Does influenza vaccine reduce major adverse cardiovascular events in high-risk patients?
Influenza vaccination is associated with a reduced risk of major adverse cardiovascular events, particularly in high-risk patients with active coronary disease.
In a meta-analysis of RCTs, the use of influenza vaccine was associated with a lower risk of major adverse cardiovascular events. The greatest treatment effect was seen among the highest-risk patients with more active coronary disease. A large, adequately powered, multicenter trial is warranted to address these findings and assess individual cardiovascular end points.
Udell et al. (Tue,) studied this question.